Cas:330942-11-5 N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide manufacturer & supplier

We serve Chemical Name:N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide CAS:330942-11-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide

Chemical Name:N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide
CAS.NO:330942-11-5
Synonyms:N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide
Molecular Formula:C21H15BrN4O3
Molecular Weight:451.2728
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.56±0.1 g/cm3 (20 ºC 760 Torr)
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide Use and application,N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide technical grade,usp/ep/jp grade.


Related News: Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide manufacturer An FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices at the Emergent plant. N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide supplier The FDA said its decision allows for the J&J doses to be used in the United States or exported. T N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide vendor During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology. N-(5-Bromo-2-pyridinyl)-2-[(4-cyanobenzoyl)amino]-5-methoxybenzamide factory An FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices at the Emergent plant.